• InnoCare Pharma dosed the first patient in a Phase I trial of ICP-B381 in China for solid tumors, including prostate cancer.
• The bispecific antibody-drug conjugate targets PSMA and STEAP1 to address tumor heterogeneity and reduce tumor escape.
• Reported preclinical results showed stronger antitumor activity than corresponding single-target treatments at the same dose, with favorable tolerability.
• No bispecific antibody-drug conjugate targeting PSMA and STEAP1 has marketing approval globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110847PRIMZONEFULLFEED9875402) on November 11, 2026, and is solely responsible for the information contained therein.